Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma

Invest New Drugs. 1994;12(4):323-5. doi: 10.1007/BF00873048.

Abstract

Fourteen patients with advanced renal cell carcinoma were treated on a phase II trial with liposomal encapsulated doxorubicin (Lipodox, LED). None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity and no cardiac toxicity was evident. Seventy-nine percent (11 of 14) of patients experienced grade III or IV neutropenia. In summary, LED did not show antitumor activity in the treatment of advanced renal cell carcinoma.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Doxorubicin / administration & dosage*
  • Drug Carriers
  • Female
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Liposomes
  • Male
  • Middle Aged

Substances

  • Drug Carriers
  • Liposomes
  • Doxorubicin